AU7962200A - Novel indole derivatives and drugs containing the same as the active ingredient - Google Patents
Novel indole derivatives and drugs containing the same as the active ingredientInfo
- Publication number
- AU7962200A AU7962200A AU79622/00A AU7962200A AU7962200A AU 7962200 A AU7962200 A AU 7962200A AU 79622/00 A AU79622/00 A AU 79622/00A AU 7962200 A AU7962200 A AU 7962200A AU 7962200 A AU7962200 A AU 7962200A
- Authority
- AU
- Australia
- Prior art keywords
- same
- active ingredient
- indole derivatives
- drugs containing
- novel indole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP31006699 | 1999-10-29 | ||
JP11/310066 | 1999-10-29 | ||
JP2000-129760 | 2000-04-28 | ||
JP2000129760 | 2000-04-28 | ||
PCT/JP2000/007590 WO2001032621A1 (en) | 1999-10-29 | 2000-10-27 | Novel indole derivatives and drugs containing the same as the active ingredient |
Publications (1)
Publication Number | Publication Date |
---|---|
AU7962200A true AU7962200A (en) | 2001-05-14 |
Family
ID=26566177
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU79622/00A Abandoned AU7962200A (en) | 1999-10-29 | 2000-10-27 | Novel indole derivatives and drugs containing the same as the active ingredient |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU7962200A (en) |
WO (1) | WO2001032621A1 (en) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7632955B2 (en) | 2001-12-13 | 2009-12-15 | National Health Research Institutes | Indole compounds |
US20030195192A1 (en) * | 2002-04-05 | 2003-10-16 | Fortuna Haviv | Nicotinamides having antiangiogenic activity |
US6875780B2 (en) * | 2002-04-05 | 2005-04-05 | Warner-Lambert Company | Compounds that modulate PPAR activity and methods for their preparation |
SE0201635D0 (en) | 2002-05-30 | 2002-05-30 | Astrazeneca Ab | Novel compounds |
TW200307542A (en) | 2002-05-30 | 2003-12-16 | Astrazeneca Ab | Novel compounds |
SE0202241D0 (en) | 2002-07-17 | 2002-07-17 | Astrazeneca Ab | Novel Compounds |
US7700583B2 (en) | 2003-04-11 | 2010-04-20 | High Point Pharmaceuticals, Llc | 11β-hydroxysteroid dehydrogenase type 1 active compounds |
EP1787982B1 (en) * | 2003-04-11 | 2010-05-12 | High Point Pharmaceuticals, LLC | 11Beta-Hydroxysteroid dehydrogenase type 1 active compounds |
SE0301569D0 (en) | 2003-05-27 | 2003-05-27 | Astrazeneca Ab | Novel compounds |
SE0302232D0 (en) | 2003-08-18 | 2003-08-18 | Astrazeneca Ab | Novel Compounds |
WO2005018672A1 (en) * | 2003-08-22 | 2005-03-03 | Teijin Pharma Limited | Drug containing chymase inhibitor as the active ingredient |
US7592466B2 (en) | 2003-10-09 | 2009-09-22 | Abbott Laboratories | Ureas having antiangiogenic activity |
CA2570363A1 (en) | 2004-06-18 | 2005-12-29 | Biolipox Ab | Indoles useful in the treatment of inflammation |
GB0500604D0 (en) | 2005-01-13 | 2005-02-16 | Astrazeneca Ab | Novel process |
WO2006077366A1 (en) | 2005-01-19 | 2006-07-27 | Biolipox Ab | Indoles useful in the treatment of inflammation |
US7977359B2 (en) | 2005-11-04 | 2011-07-12 | Amira Pharmaceuticals, Inc. | 5-lipdxygenase-activating protein (FLAP) inhibitors |
US8399666B2 (en) | 2005-11-04 | 2013-03-19 | Panmira Pharmaceuticals, Llc | 5-lipoxygenase-activating protein (FLAP) inhibitors |
GB2431927B (en) | 2005-11-04 | 2010-03-17 | Amira Pharmaceuticals Inc | 5-Lipoxygenase-activating protein (FLAP) inhibitors |
UA95788C2 (en) * | 2005-12-15 | 2011-09-12 | Ф. Хоффманн-Ля Рош Аг | Fused pyrrole derivatives |
CN101370775A (en) | 2006-01-13 | 2009-02-18 | 惠氏公司 | Sulfonyl substituted 1H-indoles as ligands for the 5-hydroxytryptamine receptors |
EP2125722A2 (en) | 2006-05-26 | 2009-12-02 | AstraZeneca AB | Bi-aryl or aryl-heteroaryl substituted indoles |
WO2008019357A2 (en) | 2006-08-07 | 2008-02-14 | Ironwood Pharmaceuticals, Inc. | Indole compounds |
JP5634263B2 (en) * | 2007-08-16 | 2014-12-03 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Quinazolinedione chymase inhibitor |
CN102137858B (en) | 2008-05-23 | 2014-07-23 | 潘米拉制药有限责任公司 | 5-lipoxygenase-activating protein inhibitor |
KR101752932B1 (en) | 2009-07-06 | 2017-07-03 | 아스트라제네카 아베 | Intermediates and processes for the preparation of 4-(acetylamino))-3-[(4-chloro-phenyl)thio]-2-methyl-1h-indole-1-acetic acid |
AR084433A1 (en) | 2010-12-22 | 2013-05-15 | Ironwood Pharmaceuticals Inc | FAAH INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
KR101400346B1 (en) | 2012-01-31 | 2014-05-30 | 인제대학교 산학협력단 | Composition for suppression of cancer metastasis containing NecroX |
WO2013115457A1 (en) * | 2012-01-31 | 2013-08-08 | 인제대학교 산학협력단 | Composition for inhibiting metastasis, containing necrox |
US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
WO2014055595A1 (en) | 2012-10-05 | 2014-04-10 | Merck Sharp & Dohme Corp. | Indoline compounds as aldosterone synthase inhibitiors related applications |
JP6064062B2 (en) | 2013-03-15 | 2017-01-18 | ファイザー・インク | Indazole compounds that activate AMPK |
WO2018165501A1 (en) * | 2017-03-10 | 2018-09-13 | Lycera Corporation | INDOLINYL SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATMENT OF DISEASE |
CN107915726B (en) * | 2017-12-06 | 2020-06-05 | 西华大学 | Novel 3, 5-disubstituted 1H-indole derivative and synthesis and application thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB869775A (en) * | 1958-09-24 | 1961-06-07 | Upjohn Co | 3-indolyl ketones |
ES2097142T3 (en) * | 1989-02-10 | 1997-04-01 | Otsuka Pharma Co Ltd | DERIVED FROM INDOL, ITS PREPARATION AND THE CONTAINING MEDICINE INTENDED FOR THE PREVENTION AND TREATMENT OF NEPHRITIS. |
US5468898A (en) * | 1990-09-10 | 1995-11-21 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Substituted naphthylene compounds exhibiting selective leukotriene B4 antagonist activity |
WO1993005020A1 (en) * | 1991-09-06 | 1993-03-18 | Merck & Co., Inc. | Indoles as inhibitors of hiv reverse transcriptase |
GB9226537D0 (en) * | 1992-12-21 | 1993-02-17 | Smithkline Beecham Plc | Compounds |
BR9405737A (en) * | 1993-02-24 | 1995-12-05 | Merck & Co Inc | Compound process of inhibiting HIV transcriptase, process for preventing HIV infection or treating HIV infection, pharmaceutical composition useful for inhibiting HIV transcriptase, and useful for preventing or treating HIV infection or for the treatment of AIDS or ARC |
US5486525A (en) * | 1993-12-16 | 1996-01-23 | Abbott Laboratories | Platelet activating factor antagonists: imidazopyridine indoles |
AU5772196A (en) * | 1995-05-19 | 1996-11-29 | Chiroscience Limited | 3,4-disubstituted-phenylsulphonamides and their therapeutic use |
EP0880519B1 (en) * | 1996-01-22 | 2002-04-17 | Fujisawa Pharmaceutical Co., Ltd. | Thiazolylbenzofuran derivatives and pharmaceutical compositions containing them |
JPH1087567A (en) * | 1996-06-05 | 1998-04-07 | Takeda Chem Ind Ltd | Phenol ester derivative, its production and use |
AUPO118896A0 (en) * | 1996-07-23 | 1996-08-15 | Fujisawa Pharmaceutical Co., Ltd. | New use |
-
2000
- 2000-10-27 WO PCT/JP2000/007590 patent/WO2001032621A1/en active Application Filing
- 2000-10-27 AU AU79622/00A patent/AU7962200A/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2001032621A1 (en) | 2001-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU7962200A (en) | Novel indole derivatives and drugs containing the same as the active ingredient | |
AU3076700A (en) | 2h-phthalazin-1-one derivatives and drugs comprising these derivatives as the active ingredient | |
AU2300699A (en) | Amidino derivatives and drugs containing the same as the active ingredient | |
AU763356C (en) | Fused-ring compounds and use thereof as drugs | |
HUP0101461A3 (en) | Novel pyridazine derivatives and drugs containing the same as the active ingredient | |
AU2319100A (en) | Amide derivatives and drug compositions | |
AU2002226674A1 (en) | Tricyclic and heterocyclic derivative compounds and drugs containing these compounds as the active ingredient | |
EP1114816A4 (en) | $g(v)-SUBSTITUTED PHENYL-PROSTAGLANDIN E DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | |
HUP0100059A3 (en) | Novel pyridazine derivatives and drugs containing the same as the active ingredient | |
AU3053199A (en) | Fused thiophene derivatives and drugs containing the same as the active ingredient | |
AU4328800A (en) | Pharmaceutical formulation | |
AU2001278772A1 (en) | Benzoic acid derivatives and drugs containing the same as the active ingredient | |
AU6309698A (en) | Drugs containing aminopyridine derivatives as the active ingredient | |
HUP0102369A3 (en) | Amino acid derivatives and drugs containing the same as the active ingredient | |
AU5647199A (en) | Carboxylic acid derivatives and drugs containing the same as the active ingredient | |
AU2001289758A1 (en) | Novel indole derivatives and their use as medicaments | |
AU3078000A (en) | Heterocyclic compounds and antitumor agents containing the same as the active ingredient | |
AU1650401A (en) | Oxadiazole derivatives and drugs containing these derivatives as the active ingredient | |
AU2001277738A1 (en) | Piperidine derivatives and drugs containing these derivatives as the active ingredient | |
HUP0201338A2 (en) | Novel indole derivatives, pharmaceutical compositions containing them and their use | |
AU5443499A (en) | Carboxylic acid derivatives and drugs containing the same as the active ingredient | |
AU3669700A (en) | 4-aminobutanoic acid derivatives and drugs containing these derivatives as the active ingredient | |
AU2001228810A1 (en) | Benzene-fused heterocycle derivatives and drugs containing the same as the active ingredient | |
AU1650501A (en) | 1,3,4-oxadiazoline derivatives and drugs containing these derivatives as the active ingredient | |
HUP0203767A3 (en) | Novel indole derivatives, pharmaceutical compositions containing them and their use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |